Figure 5: A) Difference in serum potassium after treatment with ACE/ARB combination therapy vs. monotherapy. Serum potassium was slightly (0.09 mEq/L) but not significantly higher after combination therapy. B) Difference in serum potassium after treatment with ALDOA combination therapy vs. monotherapy. Serum potassium was slightly (0.23 mEq/L) but significantly higher after combination therapy. C) Risk of hyperkalemia after treatment with ACE/ARB combination therapy vs. monotherapy. There was a 2.16-fold increased risk of hyperkalemia with combination therapy. D) Risk of hyperkalemia after treatment with ALDOA combination therapy vs. monotherapy. There was a 3.94-fold increased risk of hyperkalemia with combination therapy.